ProtEx™ technology for the generation of novel therapeutic cancer vaccines

Experimental and Molecular Pathology

Volumn 86, Issue 3, 2009, Pages 198-207

  Schabowsky, Rich Henry ^a,b   Sharma, Rajesh K ^b   Madireddi, Shravan ^a,b   Srivastava, Abhishek ^a,b   Yolcu, Esma S ^a,b   Shirwan, Haval ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CELL FREE VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; LIPOPOLYSACCHARIDE; PHOSPHORYL LIPID A; RECOMBINANT CARCINOEMBRYONIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT MUCIN1; RECOMBINANT SURVIVIN 2B PEPTIDE; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; TOLL LIKE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER IMMUNIZATION; CELL SURFACE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG FORMULATION; GENE THERAPY; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; MELANOMA; NEOPLASM; NONHUMAN; PATIENT SAFETY; TREATMENT FAILURE; TUMOR IMMUNITY; ANIMAL; BIOTECHNOLOGY; DENDRITIC CELL; DRUG POTENTIATION; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; REVIEW; SOLUBILITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; BIOTECHNOLOGY; CANCER VACCINES; DENDRITIC CELLS; GENE THERAPY; GENETIC ENGINEERING; HUMANS; NEOPLASMS; SOLUBILITY; TOLL-LIKE RECEPTORS;

EID: 67049144607     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2009.01.010     Document Type: Article

References (125)

1. Akira S., and Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4 (2004) 499-511
2. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
3. Anderson W.F. Human gene therapy. Nature 392 (1998) 25-30
4. Apostolopoulos V., Pietersz G.A., Tsibanis A., Tsikkinis A., Drakaki H., Loveland B.E., Piddlesden S.J., Plebanski M., Pouniotis D.S., Alexis M.N., McKenzie I.F., and Vassilaros S. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 8 (2006) R27
5. Askenasy N., Yolcu E.S., Shirwan H., Wang Z., and Farkas D.L. Cardiac allograft acceptance after localized bone marrow transplantation by isolated limb perfusion in nonmyeloablated recipients. Stem. Cells 21 (2003) 200-207
6. Askenasy N., Yolcu E.S., Wang Z., and Shirwan H. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation 107 (2003) 1525-1531
7. Askenasy N., Yolcu E.S., Yaniv I., and Shirwan H. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 105 (2005) 1396-1404
8. Atkins D., Breuckmann A., Schmahl G.E., Binner P., Ferrone S., Krummenauer F., Storkel S., and Seliger B. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int. J. Cancer 109 (2004) 265-273
9. Avigan D., Vasir B., Gong J., Borges V., Wu Z., Uhl L., Atkins M., Mier J., McDermott D., Smith T., Giallambardo N., Stone C., Schadt K., Dolgoff J., Tetreault J.C., Villarroel M., and Kufe D. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10 (2004) 4699-4708
10. Avigan D.E., Vasir B., George D.J., Oh W.K., Atkins M.B., McDermott D.F., Kantoff P.W., Figlin R.A., Vasconcelles M.J., Xu Y., Kufe D., and Bukowski R.M. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother. 30 (2007) 749-761
11. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin. Exp. Immunol. 39 (1980) 435-441
12. Bukczynski J., Wen T., Ellefsen K., Gauldie J., and Watts T.H. Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1291-1296
13. Cannons J.L., Lau P., Ghumman B., DeBenedette M.A., Yagita H., Okumura K., and Watts T.H. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 167 (2001) 1313-1324
14. Chianese-Bullock K.A., Irvin Jr. W.P., Petroni G.R., Murphy C., Smolkin M., Olson W.C., Coleman E., Boerner S.A., Nail C.J., Neese P.Y., Yuan A., Hogan K.T., and Slingluff Jr. C.L. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J. Immunother. 31 (2008) 420-430
15. Choi B.K., Bae J.S., Choi E.M., Kang W.J., Sakaguchi S., Vinay D.S., and Kwon B.S. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J. Leukoc. Biol. 75 (2004) 785-791
16. Coley W.B. End results in Hodgkin's Disease and lymphosarcoma treated by the mixed toxins of Erysipelas and Bacillus prodigiosus, alone or combined with radiation. Ann. Surg. 88 (1928) 641-667
17. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., and Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168 (2002) 1356-1361
18. Cuenca A., Cheng F., Wang H., Brayer J., Horna P., Gu L., Bien H., Borrello I.M., Levitsky H.I., and Sotomayor E.M. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 63 (2003) 9007-9015
19. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., and Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004) 942-949
20. Dawicki W., Bertram E.M., Sharpe A.H., and Watts T.H. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J. Immunol. 173 (2004) 5944-5951
21. de Gruijl T.D., van den Eertwegh A.J., Pinedo H.M., and Scheper R.J. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol. Immunother. 57 (2008) 1569-1577
22. den Haan J.M., Kraal G., and Bevan M.J. Cutting edge: lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response. J. Immunol. 178 (2007) 5429-5433
23. Dighe A.S., Richards E., Old L.J., and Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1 (1994) 447-456
24. Disis M.L., Scholler N., Dahlin A., Pullman J., Knutson K.L., Hellstrom K.E., and Hellstrom I. Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. Mol. Cancer Ther. 2 (2003) 995-1002
25. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2004) 137-148
26. Elpek K.G., Lacelle C., Singh N.P., Yolcu E.S., and Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J. Immunol. 178 (2007) 6840-6848
27. Elpek K.G., Yolcu E.S., Franke D.D., Lacelle C., Schabowsky R.H., and Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J. Immunol. 179 (2007) 7295-7304
28. Ferlin W.G., von der Weid T., Cottrez F., Ferrick D.A., Coffman R.L., and Howard M.C. The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb. Eur. J. Immunol. 28 (1998) 525-531
29. Franke D.D., Yolcu E.S., Alard P., Kosiewicz M.M., and Shirwan H. A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model. Mol. Immunol. 44 (2007) 2884-2892
30. Futagawa T., Akiba H., Kodama T., Takeda K., Hosoda Y., Yagita H., and Okumura K. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 14 (2002) 275-286
31. Gao Y., Yang W., Pan M., Scully E., Girardi M., Augenlicht L.H., Craft J., and Yin Z. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med. 198 (2003) 433-442
32. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., and Nemazee D. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314 (2006) 1936-1938
33. Girardi M., Oppenheim D.E., Steele C.R., Lewis J.M., Glusac E., Filler R., Hobby P., Sutton B., Tigelaar R.E., and Hayday A.C. Regulation of cutaneous malignancy by gammadelta T cells. Science 294 (2001) 605-609
34. Goodell V., Salazar L.G., Urban N., Drescher C.W., Gray H., Swensen R.E., McIntosh M.W., and Disis M.L. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J. Clin. Oncol. 24 (2006) 762-768
35. Govan V.A. A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). Ther. Clin. Risk Manag. 4 (2008) 65-70
36. Grakoui A., Bromley S.K., Sumen C., Davis M.M., Shaw A.S., Allen P.M., and Dustin M.L. The immunological synapse: a molecular machine controlling T cell activation. Science 285 (1999) 221-227
37. Granger S.W., and Rickert S. LIGHT-HVEM signaling and the regulation of T cell-mediated immunity. Cytokine Growth Factor Rev. 14 (2003) 289-296
38. Green N.M. Avidin and streptavidin. Methods Enzymol. 184 (1990) 51-67
39. Grun J.L., and Maurer P.H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol. 121 (1989) 134-145
40. Gückel B., Stumm S., Rentzsch C., Marmé A., Mannhardt G., and Wallwiener D. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo. Cancer Immunol. Immunother. 54 2 (2005) 129-140
41. Haanen J.B., Baars A., Gomez R., Weder P., Smits M., de Gruijl T.D., von Blomberg B.M., Bloemena E., Scheper R.J., van Ham S.M., Pinedo H.M., and van den Eertwegh A.J. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol. Immunother. 55 (2006) 451-458
42. Hixon J.A., Anver M.R., Blazar B.R., Panoskaltsis-Mortari A., Wiltrout R.H., and Murphy W.J. Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut. Biol. Blood Marrow Transplant. 8 (2002) 316-325
43. Hixon J.A., Blazar B.R., Anver M.R., Wiltrout R.H., and Murphy W.J. Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation. Biol. Blood Marrow Transplant. 7 (2001) 136-143
44. Hofbauer G.F., Baur T., Bonnet M.C., Tartour E., Burg G., Berinstein N.L., and Dummer R. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Res. 18 (2008) 104-111
45. Hollenbeak C.S., Todd M.M., Billingsley E.M., Harper G., Dyer A.M., and Lengerich E.J. Increased incidence of melanoma in renal transplantation recipients. Cancer 104 (2005) 1962-1967
46. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., and Chen S.H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66 (2006) 1123-1131
47. Igney F.H., and Krammer P.H. Tumor counterattack: fact or fiction?. Cancer Immunol. Immunother. 54 (2005) 1127-1136
48. Ishii K.J., and Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 27 (2007) 363-371
49. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20 (2002) 197-216
50. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., and Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 7556-7561
51. Kasimir-Bauer S., Mayer S., Bojko P., Borquez D., Neumann R., and Seeber S. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy. Clin. Cancer Res. 7 6 (2001) 1582-1589
52. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Drijfhout J.W., Wafelman A.R., Oostendorp J., Fleuren G.J., Offringa R., van der Burg S.H., and Melief C.J. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14 (2008) 169-177
53. Kienzle G., and von Kempis J. CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. Int. Immunol. 12 (2000) 73-82
54. Kilinc M.O., Mukundan L., Yolcu E.S., Singh N.P., Suttles J., and Shirwan H. Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon. Exp. Mol. Pathol. 80 (2006) 252-261
55. Knutson K.L., Dang Y., Lu H., Lukas J., Almand B., Gad E., Azeke E., and Disis M.L. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 177 (2006) 84-91
56. Knutson K.L., Schiffman K., Cheever M.A., and Disis M.L. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin. Cancer Res. 8 (2002) 1014-1018
57. Krieg A.M. Toll-free vaccines?. Nat. Biotechnol. 25 (2007) 303-305
58. Lavergne E., Combadiere C., Iga M., Boissonnas A., Bonduelle O., Maho M., Debre P., and Combadiere B. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J. Immunol. 173 (2004) 3755-3762
59. Lee P.K., Chang C.J., and Lin C.M. Lipopolysaccharide preferentially induces 4-1BB ligand expression on human monocyte-derived dendritic cells. Immunol. Lett. 90 (2003) 215-221
60. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., and Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24 (2006) 99-146
61. Liu V.C., Wong L.Y., Jang T., Shah A.H., Park I., Yang X., Zhang Q., Lonning S., Teicher B.A., and Lee C. Tumor evasion of the immune system by converting CD4+. J. Immunol. 178 (2007) 2883-2892
62. Mancheno-Corvo P., and Martin-Duque P. Viral gene therapy. Clin. Transl. Oncol. 8 (2006) 858-867
63. Mattioni M., Soddu S., Porrello A., D'Alessandro R., Spila A., and Guadagni F. Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma. Int. J. Biol. Markers 22 (2007) 302-306
64. McHugh R.S., Whitters M.J., Piccirillo C.A., Young D.A., Shevach E.M., Collins M., and Byrne M.C. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16 (2002) 311-323
65. McKee A.S., Munks M.W., and Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27 (2007) 687-690
66. Melero I., Murillo O., Dubrot J., Hervas-Stubbs S., and Perez-Gracia J.L. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol. Sci. 29 (2008) 383-390
67. Mellor A.L., Baban B., Chandler P.R., Manlapat A., Kahler D.J., and Munn D.H. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J. Immunol. 175 (2005) 5601-5605
68. Meyer-Bahlburg A., Khim S., and Rawlings D.J. B cell intrinsic TLR signals amplify but are not required for humoral immunity. J. Exp. Med. 204 (2007) 3095-3101
69. Miller R.E., Jones J., Le T., Whitmore J., Boiani N., Gliniak B., and Lynch D.H. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol. 169 (2002) 1792-1800
70. Moseman E.A., Liang X., Dawson A.J., Panoskaltsis-Mortari A., Krieg A.M., Liu Y.J., Blazar B.R., and Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J. Immunol. 173 (2004) 4433-4442
71. Myers L., Lee S.W., Rossi R.J., Lefrancois L., Kwon B.S., Mittler R.S., Croft M., and Vella A.T. Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int. Immunol. 18 (2006) 325-333
72. Nelson W.G., Simons J.W., Mikhak B., Chang J.F., DeMarzo A.M., Carducci M.A., Kim M., Weber C.E., Baccala A.A., Goeman M.A., Clift S.M., Ando D.G., Levitsky H.I., Cohen L.K., Sanda M.G., Mulligan R.C., Partin A.W., Carter H.B., Piantadosi S., and Marshall F.F. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother. Pharmacol. 46 (2000) S67-S72 (Suppl)
73. Niu L., Strahotin S., Hewes B., Zhang B., Zhang Y., Archer D., Spencer T., Dillehay D., Kwon B., Chen L., Vella A.T., and Mittler R.S. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J. Immunol. 178 (2007) 4194-4213
74. O'Malley W.E., Achinstein B., and Shear M.J. Action of bacterial polysaccharide on tumors. III. Repeated responses of sarcoma 37, in tolerant mice, to Serratia marcescens endotoxin. Cancer Res. 23 (1963) 890-895
75. Old L.J. Tumor necrosis factor (TNF). Science 230 (1985) 630-632
76. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., Meatchi T., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., and Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353 (2005) 2654-2666
77. Pauly S., Broll K., Wittmann M., Giegerich G., and Schwarz H. CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J. Leukoc. Biol. 72 (2002) 35-42
78. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 23 (2000) 101-113
79. Rabu C., Quemener A., Jacques Y., Echasserieau K., Vusio P., and Lang F. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J. Biol. Chem. 280 (2005) 41472-41481
80. Reznik G.O., Vajda S., Sano T., and Cantor C.R. A streptavidin mutant with altered ligand-binding specificity. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13525-13530
81. Roman L.D., Wilczynski S., Muderspach L.I., Burnett A.F., O'Meara A., Brinkman J.A., Kast W.M., Facio G., Felix J.C., Aldana M., and Weber J.S. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol. Oncol. 106 (2007) 558-566
82. Salazar-Onfray F. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med. Oncol. 16 (1999) 86-94
83. Sansonetti P.J. The innate signaling of dangers and the dangers of innate signaling. Nat. Immunol. 7 (2006) 1237-1242
84. Sas S., Chan T., Sami A., El-Gayed A., and Xiang J. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice. Cancer Gene Ther. 15 (2008) 655-666
85. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., Kepner J., Odunsi T., Ritter G., Lele S., Chen Y.T., Ohtani H., Old L.J., and Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18538-18543
86. Schabowsky R.H., Madireddi S., Sharma R., Yolcu E.S., and Shirwan H. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr. Opin. Investig. Drugs 8 (2007) 1002-1008
87. Seliger B., Maeurer M.J., and Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21 (2000) 455-464
88. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., and Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
89. Singh N.P., Miller R.W., Yolcu E.S., Kilinc M.O., Oechsli M., Huseby R., Taylor D.D., Perry M.T., Larocca R.V., and Shirwan H. Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo. Hum. Gene Ther. 17 (2006) 334-346
90. Singh N.P., Yolcu E.S., Askenasy N., and Shirwan H. ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation. Ann. N. Y. Acad. Sci. 1056 (2005) 344-358
91. Singh N.P., Yolcu E.S., Taylor D.D., Gercel-Taylor C., Metzinger D.S., Dreisbach S.K., and Shirwan H. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Res. 63 (2003) 4067-4073
92. Smyth M.J., Dunn G.P., and Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90 (2006) 1-50
93. Smyth M.J., Thia K.Y., Street S.E., MacGregor D., Godfrey D.I., and Trapani J.A. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192 (2000) 755-760
94. So T., Takenoyama M., Mizukami M., Ichiki Y., Sugaya M., Hanagiri T., Sugio K., and Yasumoto K. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res. 65 (2005) 5945-5952
95. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., Krieg A.M., Cerottini J.C., and Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest 115 (2005) 739-746
96. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., and Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355 (2006) 1018-1028
97. Tao G., Hu J., Zou H., Lin Q., Liu F., Wu Y., and Sun Q. Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene. Chin. Med. J. (Engl.) 114 (2001) 623-627
98. Townsend S.E., and Allison J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259 (1993) 368-370
99. Tsuruma T., Iwayama Y., Ohmura T., Katsuramaki T., Hata F., Furuhata T., Yamaguchi K., Kimura Y., Torigoe T., Toyota N., Yagihashi A., Hirohashi Y., Asanuma H., Shimozawa K., Okazaki M., Mizushima Y., Nomura N., Sato N., and Hirata K. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J. Transl. Med. 6 (2008) 24
100. Ullenhag G.J., Frodin J.E., Jeddi-Tehrani M., Strigard K., Eriksson E., Samanci A., Choudhury A., Nilsson B., Rossmann E.D., Mosolits S., and Mellstedt H. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin. Cancer Res. 10 (2004) 3273-3281
101. Uno T., Takeda K., Kojima Y., Yoshizawa H., Akiba H., Mittler R.S., Gejyo F., Okumura K., Yagita H., and Smyth M.J. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12 (2006) 693-698
102. van Mierlo G.J., den Boer A.T., Medema J.P., van der Voort E.I., Fransen M.F., Offringa R., Melief C.J., and Toes R.E. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 5561-5566
103. Van P.A., and Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 4718-4722
104. Vonderheide R.H., Flaherty K.T., Khalil M., Stumacher M.S., Bajor D.L., Hutnick N.A., Sullivan P., Mahany J.J., Gallagher M., Kramer A., Green S.J., O'Dwyer P.J., Running K.L., Huhn R.D., and Antonia S.J. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25 (2007) 876-883
105. Wada H., Sato E., Uenaka A., Isobe M., Kawabata R., Nakamura Y., Iwae S., Yonezawa K., Yamasaki M., Miyata H., Doki Y., Shiku H., Jungbluth A.A., Ritter G., Murphy R., Hoffman E.W., Old L.J., Monden M., and Nakayama E. Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination. Int. J. Cancer 123 (2008) 2362-2369
106. Waller E.C., McKinney N., Hicks R., Carmichael A.J., Sissons J.G., and Wills M.R. Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific "effector memory" (CD28(-) CD45RA(HI)) CD8(+) T cells. Blood 110 (2007) 4360-4366
107. Ward S., Casey D., Labarthe M.C., Whelan M., Dalgleish A., Pandha H., and Todryk S. Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 51 (2002) 351-357
108. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23 (2005) 23-68
109. Weber J., Boswell W., Smith J., Hersh E., Snively J., Diaz M., Miles S., Liu X., Obrocea M., Qiu Z., and Bot A. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J. Immunother. 31 (2008) 215-223
110. Webster W.S., Thompson R.H., Harris K.J., Frigola X., Kuntz S., Inman B.A., and Dong H. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J. Immunol. 179 (2007) 2860-2869
111. Welters M.J., Kenter G.G., Piersma S.J., Vloon A.P., Lowik M.J., Berends-van der Meer D.M., Drijfhout J.W., Valentijn A.R., Wafelman A.R., Oostendorp J., Fleuren G.J., Offringa R., Melief C.J., and van der Burg S.H. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14 (2008) 178-187
112. Wierecky J., Muller M.R., Wirths S., Halder-Oehler E., Dorfel D., Schmidt S.M., Hantschel M., Brugger W., Schroder S., Horger M.S., Kanz L., and Brossart P. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 66 (2006) 5910-5918
113. Wilcox R.A., Flies D.B., Zhu G., Johnson A.J., Tamada K., Chapoval A.I., Strome S.E., Pease L.R., and Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109 (2002) 651-659
114. Wilcox R.A., Tamada K., Strome S.E., and Chen L. Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J. Immunol. 169 (2002) 4230-4236
115. Yang W., Guo C., Liu Q.G., and Pan C. Experimental study of specific immunotherapy induced by H22 autologous tumor as whole tumor cell vaccine. Biomed. Pharmacother. (2008) Sep 18. [Epub ahead of print]
116. Yang Z.Z., Novak A.J., Stenson M.J., Witzig T.E., and Ansell S.M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107 (2006) 3639-3646
117. Yolcu E.S., Askenasy N., Singh N.P., Cherradi S.E., and Shirwan H. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 17 (2002) 795-808
118. Yolcu E.S., Gu X., Lacelle C., Zhao H., Bandura-Morgan L., Askenasy N., and Shirwan H. Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein. J. Immunol. 181 (2008) 931-939
119. Yu P., and Fu Y.X. Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev. 19 (2008) 285-294
120. Yu P., Lee Y., Liu W., Krausz T., Chong A., Schreiber H., and Fu Y.X. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201 (2005) 779-791
121. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., and Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003) 203-213
122. Zhang M., Berndt B.E., Chen J.J., and Kao J.Y. Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy. J. Immunol. 181 (2008) 3690-3697
123. Zheng G., Wang B., and Chen A. The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells. J. Immunol. 173 (2004) 2428-2434
124. Zhou Z., Kim S., Hurtado J., Lee Z.H., Kim K.K., Pollok K.E., and Kwon B.S. Characterization of human homologue of 4-1BB and its ligand. Immunol. Lett. 45 (1995) 67-73
125. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5 (2005) 263-274